Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
VBLT Stock Overview
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States.
Vascular Biogenics Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.49 |
52 Week High | US$2.59 |
52 Week Low | US$1.10 |
Beta | 1.08 |
1 Month Change | -15.82% |
3 Month Change | -11.31% |
1 Year Change | -36.86% |
3 Year Change | 14.62% |
5 Year Change | -66.52% |
Change since IPO | -74.53% |
Recent News & Updates
Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Shareholder Returns
VBLT | US Biotechs | US Market | |
---|---|---|---|
7D | 9.6% | 10.3% | 6.6% |
1Y | -36.9% | -24.3% | -18.4% |
Return vs Industry: VBLT underperformed the US Biotechs industry which returned -24.4% over the past year.
Return vs Market: VBLT underperformed the US Market which returned -18.5% over the past year.
Price Volatility
VBLT volatility | |
---|---|
VBLT Average Weekly Movement | 11.7% |
Biotechs Industry Average Movement | 13.2% |
Market Average Movement | 8.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VBLT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: VBLT's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 41 | Dror Harats | https://www.vblrx.com |
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company’s lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer.
Vascular Biogenics Fundamentals Summary
VBLT fundamental statistics | |
---|---|
Market Cap | US$103.33m |
Earnings (TTM) | -US$34.06m |
Revenue (TTM) | US$696.00k |
148.6x
P/S Ratio-3.0x
P/E RatioIs VBLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VBLT income statement (TTM) | |
---|---|
Revenue | US$696.00k |
Cost of Revenue | US$330.00k |
Gross Profit | US$366.00k |
Other Expenses | US$34.43m |
Earnings | -US$34.06m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.49 |
Gross Margin | 52.59% |
Net Profit Margin | -4,894.40% |
Debt/Equity Ratio | 0% |
How did VBLT perform over the long term?
See historical performance and comparisonValuation
Is VBLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VBLT?
Other financial metrics that can be useful for relative valuation.
What is VBLT's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$103.33m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 87.7x |
Enterprise Value/EBITDA | -1.9x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does VBLT's PB Ratio compare to its peers?
VBLT PB Ratio vs Peers |
---|
Company | PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.8x |
Price-To-Book vs Peers: VBLT is expensive based on its Price-To-Book Ratio (2.4x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does VBLT's PE Ratio compare vs other companies in the U.S. Biotechs Industry?
Price-To-Book vs Industry: VBLT is expensive based on its Price-To-Book Ratio (2.4x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is VBLT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 2.4x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate VBLT's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of VBLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: VBLT ($1.49) is trading below our estimate of fair value ($71.8)
Significantly Below Fair Value: VBLT is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VBLT's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Vascular Biogenics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
19.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VBLT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VBLT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VBLT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VBLT's revenue (22% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: VBLT's revenue (22% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VBLT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Vascular Biogenics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-16.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VBLT is currently unprofitable.
Growing Profit Margin: VBLT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VBLT is unprofitable, and losses have increased over the past 5 years at a rate of 16.9% per year.
Accelerating Growth: Unable to compare VBLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VBLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: VBLT has a negative Return on Equity (-79.59%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Vascular Biogenics's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: VBLT's short term assets ($46.5M) exceed its short term liabilities ($11.0M).
Long Term Liabilities: VBLT's short term assets ($46.5M) exceed its long term liabilities ($2.4M).
Debt to Equity History and Analysis
Debt Level: VBLT is debt free.
Reducing Debt: VBLT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VBLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VBLT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 12% each year.
Discover healthy companies
Dividend
What is Vascular Biogenics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VBLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VBLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VBLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VBLT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as VBLT has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
14.4yrs
Average management tenure
CEO
Dror Harats (64 yo)
21.42yrs
Tenure
US$888,799
Compensation
Prof. Dror Harats, MD, has been the Chief Executive Officer of Vascular Biogenics Ltd., since January 2001. Prof. Harats founded VBL in 2000 based on many years of research in Atherosclerosis, Vascular Bio...
CEO Compensation Analysis
Compensation vs Market: Insufficient data to establish whether Dror's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Dror's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: VBLT's management team is seasoned and experienced (14.4 years average tenure).
Board Members
Experienced Board: VBLT's board of directors are considered experienced (4.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.
Top Shareholders
Company Information
Vascular Biogenics Ltd.'s employee growth, exchange listings and data sources
Key Information
- Name: Vascular Biogenics Ltd.
- Ticker: VBLT
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$103.330m
- Shares outstanding: 69.35m
- Website: https://www.vblrx.com
Number of Employees
Location
- Vascular Biogenics Ltd.
- 8 HaSatat Street
- Hevel Modi'in
- 7178106
- Israel
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.